Mirror Pharms Report issue

For profit Phase 3
Founded: Fairfield NJ United States (2010)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2021
NCT04441047
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Mirror Biologics, Inc. | MIRROR PHARMS | MIRROR PHARMS LLC

Active Ingredients

Marketed Drugs (4)

acetaminophen (tylenol) (2008)

butalbital (fiornal) (2008)

caffeine (2008)

propoxyphene (Darvon) (2008)

Drugs in Phase 3 Trials (4)

allostim (3 trials)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4